Pancreatic Cysts: Stable & Low-Risk Outcomes
- Patients with small and slow-growing pancreatic cysts are at a lower risk of developing high-grade dysplasia or pancreatic cancer, according to a study spanning 44 centers across Europe...
- Levink of Erasmus University Medical Center in Rotterdam, Netherlands, included 975 patients with neoplastic and undefined pancreatic cysts.
- The study defined high-risk stigmata as obstructive jaundice in patients with pancreatic head cysts, an enhancing mural nodule of 5 mm or larger, a main pancreatic duct of...
Patients with small,slow-growing pancreatic cysts face a significantly lower risk of developing high-grade dysplasia or pancreatic cancer. This pivotal research,drawn from a multicenter study,reveals the key role of pancreatic cyst size and growth rate in risk assessment.The study, published June 25, 2025, highlights that cysts smaller than 15 mm and those growing less than 2.5 mm per year pose a substantially reduced threat, offering crucial insights for patients. Furthermore, findings indicate that individuals with stable cysts, as defined by the study’s parameters, do not exhibit an elevated risk compared to the general population. Read the entire article on News Directory 3 for more details. Discover what’s next in the ongoing inquiry into low-risk pancreatic cysts.
Pancreatic Cyst Size, Growth Linked to Cancer Risk
Updated June 25, 2025
Patients with small and slow-growing pancreatic cysts are at a lower risk of developing high-grade dysplasia or pancreatic cancer, according to a study spanning 44 centers across Europe and North America. The research, which examined nearly 1,000 patients, highlights the importance of cyst size and growth rate in assessing risk.
The study, led by iris J.M. Levink of Erasmus University Medical Center in Rotterdam, Netherlands, included 975 patients with neoplastic and undefined pancreatic cysts. The median age of participants was 67, and 65% were women. Researchers tracked the growth of high-grade dysplasia (HGD) or pancreatic cancer (PC) over a 24-month follow-up period.
The study defined high-risk stigmata as obstructive jaundice in patients with pancreatic head cysts, an enhancing mural nodule of 5 mm or larger, a main pancreatic duct of 10 mm or larger, or suspicious cytology. Worrisome features included recent acute pancreatitis, elevated CA19-9 levels, new-onset diabetes, an enhancing mural nodule under 5 mm, a thickened cyst wall, a main pancreatic duct measuring 5-10 mm, or lymphadenopathy.
The findings indicated that patients with cysts smaller than 15 mm had a 1.5-fold lower risk of developing worrisome features or high-risk stigmata.Moreover, those with cysts growing less than 2.5 mm per year had a 2.8-fold lower risk of developing worrisome features and a 25-fold lower risk of developing HGD or PC.
Researchers resolute that the lowest absolute risk was observed in patients with a baseline cyst size less than 15 mm and growth under 2.5 mm per year. Compared to the general population, these patients did not show an increased risk for HGD or PC.
“Low‐risk cysts should be a focal point of attention for future studies aiming to alleviate the burden on patients and health care resources by reducing the intensity of follow‐up regimes or even discontinuing surveillance after years of stability,” the study authors wrote.
What’s next
The study authors suggest that future research should focus on low-risk cysts to perhaps reduce the intensity of follow-up or even discontinue surveillance for patients with stable cysts over several years.